Shanghai bestlink Biotechnology Co., Ltd

The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer and endometrial cancer. It will also learn about the safety of BL0175. The main questions it aims to answer are:
* Does the investigational drug BL0175 is safe for participants after dosed -multiple times?
* Which is the highest safety dose of BL0175 after multiple dose?
* What medical problems do participants have when using BL0175?
* Does the investigational drug BL0175 works for participants after dosed -multiple times?

主要目的：评价BL0006在晚期实体肿瘤受试者中的安全性和耐受性，探索最大耐受剂量（MTD）和II期推荐剂量（RP2D）。 次要目的：评价BL0006在晚期实体肿瘤受试者中的药代动力学（PK）特征；评价BL0006在晚期实体肿瘤受试者中的初步疗效。 探索性目的：如条件允许，探索剂量、暴露量和响应之间的关系。

This is the first in human study of BL0006, and the primary objective is to evaluate the safety and tolerability of BL0006 as a single agent in patients with advanced solid tumors.